Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Noctrix Health

Request full access

Early-stage medical device company that focuses on developing a revolutionary therapy for a chronic illness

Pleasanton, United StatesFounded 2018Health Tech & Medtech

About Noctrix Health

Noctrix Health, Inc. provides a focused non-pharmacologic therapy for a specific subset of patients with chronic neurological conditions. The company operates within the medical device and therapeutic wearables market, targeting individuals with moderate-to-severe, medication-refractory Restless Legs Syndrome (RLS). Its business model centers on a prescription-based approach, making its device available to patients through healthcare providers.

The company's origins trace back to the Stanford Biodesign Innovation Program, where the significant unmet need for better RLS treatments was identified. Founded in 2016 and incorporated in 2018 by Shriram Raghunathan and Jonathan Charlesworth, the firm was built on a foundation of combined expertise. Raghunathan, President and CEO, has a background in engineering, neuromodulation, and medical device design, while Charlesworth contributes his experience as a neuroscientist. Their collaboration aims to establish wearable therapeutics as a standard treatment option for RLS patients.

Noctrix Health's primary offering is the NTX100 Tonic Motor Activation (TOMAC) System, marketed as Nidra™. This prescription device consists of a pair of bands worn on the lower legs during the night. The system works by delivering electrical impulses to the peroneal nerves, which generates a sustained, low-level muscle activation. This neurostimulation is designed to be compatible with sleep and effectively suppresses the uncomfortable sensations characteristic of RLS. The key benefit is providing relief and improving sleep quality for patients who have not found success with or cannot tolerate pharmaceutical treatments. A notable milestone was achieved in April 2023, when the U.S. Food and Drug Administration (FDA) granted De Novo marketing authorization for the NTX100 system, following a 'Breakthrough Device Designation' in 2020. This authorization was supported by a successful multi-center, randomized controlled trial involving 133 patients, which demonstrated the therapy's efficacy and safety.

Source: Dealroom company data

At a glance

Status
Acquired
Employees
163
Open positions
46
Dealroom signal
94.4/100
Industry
Health
Sub-industry
Medical Devices
Sector
Neurology, Neuromodulation and Neurostimulation, Chronic Disease, Non-Invasive medical devices and treatments, Wearable, Hard Tech, DT and LS, science-based
Technology
Deep Tech
Business model
Manufacturing
Client focus
B2B

Funding history

8 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITIONOther financing May 2026 $360M $360M ResMed ↗
DEBTDebt Aug 2025 $17M — Western Alliance Bank · INSOUTH Bank - Member FDIC ↗
Showing the latest 2 of 8 recorded eventsBook a demo for the full funding history →

Growth signals

Noctrix Health website traffic

Latest recorded traffic for Noctrix Health is 6.5K monthly website visits, up 75.7% over the last three months. Noctrix Health's team grew 40.5% over the past year.

Latest monthly visits6.5K 3-month web change+75.7% 1-year team growth+40.5%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Noctrix Health in the Pleasanton ecosystem

Live from Dealroom

The Noctrix Health office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

Series B and later7 investors entered at this stage

  • Angelini Ventures
  • Sectoral Asset Management
  • ResMed
  • Western Alliance Bank
  • INSOUTH Bank - Member FDIC
  • Sandbox Industries
  • Blue Venture Fund
Team profiled 8 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See Noctrix Health’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.